Xencor, Inc. (NASDAQ:XNCR) Receives $24.86 Average Price Target from Brokerages

Xencor, Inc. (NASDAQ:XNCR) has received a consensus rating of “Moderate Buy” from the nine ratings firms that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, five have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $30.7143.

A number of analysts recently issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Xencor in a report on Wednesday, June 24th. Royal Bank Of Canada lifted their target price on Xencor from $19.00 to $20.00 and gave the company an “outperform” rating in a report on Thursday, August 6th. Wedbush upped their price target on Xencor from $26.00 to $30.00 and gave the company an “outperform” rating in a research report on Thursday, August 6th. Wall Street Zen raised shares of Xencor from a “strong sell” rating to a “hold” rating in a report on Saturday, August 8th. Finally, Raymond James Financial raised their price objective on shares of Xencor from $40.00 to $46.00 and gave the company a “strong-buy” rating in a research report on Tuesday.

Xencor Trading Down 0.0%

Xencor stock opened at $26.61 on Tuesday. The firm has a 50 day simple moving average of $21.06 and a 200 day simple moving average of $15.30. Xencor has a 1-year low of $8.19 and a 1-year high of $30.61. The firm has a market capitalization of $1.98 billion, a price-to-earnings ratio of -12.26 and a beta of 0.88.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.51. The firm had revenue of $51.22 million during the quarter, compared to analyst estimates of $18.89 million. Xencor had a negative return on equity of 28.66% and a negative net margin of 155.59%.The business’s revenue for the quarter was up 17.4% on a year-over-year basis. During the same period last year, the company earned ($0.41) earnings per share. On average, equities research analysts forecast that Xencor will post -3 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Tower Research Capital LLC TRC raised its position in shares of Xencor by 118.4% in the second quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company’s stock worth $44,000 after buying an additional 3,018 shares in the last quarter. Allworth Financial LP purchased a new position in Xencor during the second quarter worth about $55,000. E Fund Management Co. Ltd. purchased a new position in Xencor during the second quarter worth about $79,000. iSAM Funds UK Ltd bought a new position in Xencor in the 2nd quarter worth about $122,000. Finally, Prelude Capital Management LLC bought a new position in Xencor in the 3rd quarter worth about $139,000.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.